NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.
NovaVive offers a USDA-approved immunotherapeutic, Equimune®, which has been recommended as a preventative treatment in horses exposed to Equine Herpes Virus (EHV-1). EHV-1 outbreaks are occurring with increasing frequency.
learn more
Data from a study conducted by Gluck Equine Research Center (UKY) and Rood & Riddle Equine Hospital has demonstrated efficacy of Settle® to treat endometrial cups in mares. No other treatment has been found effective to date.
learn more
A paper has been published in the Australian Veterinary Journal, “The innate immune stimulant Amplimune® is safe to administer to young feedlot cattle”, summarizing a research study conducted by CSIRO.
learn more
